Literature DB >> 6337660

Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size.

K M Johnston, B A MacLeod, M J Walker.   

Abstract

1 The effects of pretreatment with aspirin, and of prostacyclin (PGI(2)) infusions, on responses to myocardial ischaemia and infarction produced by ligation of a coronary artery were investigated in conscious rats.2 Surgical preparation, under halothane anaesthesia, consisted of implanting exteriorized aortic and jugular cannulae, ECG leads and a polypropylene/polyethylene occluder for the left anterior descending coronary artery. Ligation of the coronary artery was performed six to nine days after surgery.3 Aspirin pretreatment consisted of 100 mg/kg given intravenously 1 or 36 h before ligation. PGI(2) infusions (10-400 ng kg(-1) min(-1), i.v.) were begun 2 min before ligation and continued for 4 h afterwards.4 ECG, blood pressure, heart rate and arrhythmias were recorded starting 30 min before, and continuing for 4 h after, ligation. Twenty-four hours after ligation, in surviving animals, the heart was removed for estimation of occluded and infarcted zones.5 Some treatments provided antiarrhythmic and other protection in the first 30 min post-ligation. By 4 and 24 h post-ligation, protective effects were lost.6 Both aspirin pretreatment and low doses of prostacyclin reduced arrhythmias occurring within 30 min of ligation. The highest dose of prostacylin (400 ng kg(-1) min(-1)) was arrhythmogenic.7 None of the treatments influenced the amount of cardiac tissue occluded or infarcted by ligation.8 The conclusions from this study in conscious rats were that acute aspirin pretreatment and low doses of infused prostacyclin have limited beneficial actions which are mainly confined to the earliest post-ligation period.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6337660      PMCID: PMC2044788          DOI: 10.1111/j.1476-5381.1983.tb09359.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Differential inhibition of prostacyclin production and platelet aggregation by aspirin.

Authors:  G Masotti; G Galanti; L Poggesi; R Abbate; G G Neri Serneri
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

2.  Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia.

Authors:  A M Lefer; M L Ogletree; J B Smith; M J Silver; K C Nicolaou; W E Barnette; G P Gasic
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

3.  Actions of prostaglandins I2 and E2 on coronary occlusion-induced arrhythmias in the rat.

Authors:  T L Au; G A Collins; C J Harvie; M J Walker
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1980

4.  Aspirin, thromboxane, and prostacyclin in rats: A dilemma resolved?

Authors:  M Livio; S Villa; G de Gaetano
Journal:  Lancet       Date:  1978-06-17       Impact factor: 79.321

5.  The action of prostaglandin E2 and F1alpha on myocardial ischaemia-infarction arrhythmias in the dog.

Authors:  C J Harvie; G A Collins; R T Miyagishima; M J Walker
Journal:  Prostaglandins       Date:  1978-12

6.  A method for administration of prolonged intravenous infusion of prostacyclin (PGI2) to unanesthetized rats.

Authors:  J R Weeks
Journal:  Prostaglandins       Date:  1979-04

7.  Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy.

Authors:  R Korbut; S Moncada
Journal:  Thromb Res       Date:  1978-09       Impact factor: 3.944

8.  The actions of prostaglandins I2 and E2 on arrhythmias produced by coronary occlusion in the rat and dog.

Authors:  T L Au; G A Collins; C J Harvie; M J Walker
Journal:  Prostaglandins       Date:  1979-11

9.  Studies on the protective effect of prostacyclin in acute myocardial ischemia.

Authors:  M L Ogletree; A M Lefer; J B Smith; K C Nicolaou
Journal:  Eur J Pharmacol       Date:  1979-06       Impact factor: 4.432

10.  Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion.

Authors:  C B Moschos; B Haider; C De La Cruz; M M Lyons; T J Regan
Journal:  Circulation       Date:  1978-04       Impact factor: 29.690

View more
  8 in total

Review 1.  Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

2.  Exercise training, indomethacin, and isoproterenol-induced myocardial necrosis in the rat.

Authors:  G R Brodowicz; D R Lamb
Journal:  Basic Res Cardiol       Date:  1991 Jan-Feb       Impact factor: 17.165

3.  The effects of metoprolol and dazmegrel, alone and in combination, on arrhythmias induced by coronary artery occlusion in conscious rats.

Authors:  I Leprán; J R Parratt; L Szekeres; C L Wainwright
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

4.  Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death.

Authors:  V B Fiedler; M Mardin
Journal:  Basic Res Cardiol       Date:  1986 Jan-Feb       Impact factor: 17.165

5.  Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat.

Authors:  M J Curtis; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

6.  Cardioprotective actions of wild garlic (allium ursinum) in ischemia and reperfusion.

Authors:  B Rietz; H Isensee; H Strobach; S Makdessi; R Jacob
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

7.  Cardioprotective actions of pentoxifylline in an animal model of acute myocardial ischaemia.

Authors:  W Gallenkämper; W Rücker; K Schrör
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

8.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.